Literature DB >> 6307602

Cefotaxime levels in ventricular cerebrospinal fluid, determined by bioassay and by high-performance liquid chromatography.

O Brückner, H Collmann, K Borner.   

Abstract

Five series of cerebrospinal fluid (CSF) samples, obtained from external ventricular drains (EVD) of 4 neurosurgical patients with cefotaxime treatment were tested simultaneously by high-performance liquid chromatography (HPLC) and microbioassay using E. coli V 6311/65 as test organism. Higher cefotaxime (CTX) concentrations in CSF were measured by the microbioassay method in 4 of the 5 series, reflecting the microbioassay being influenced by increasing amounts of desacetyl-cefotaxime (DAC) during the post-application interval. Decrease of CTX levels in CSF was consistently faster in tests performed by HPLC than those using microbioassay. The clinical efficacy in gram-negative bacillary meningitis is to be explained by levels of the parent compound CTX in CSF which are several times higher than the minimal inhibitory concentrations (MICs) of most enterobacteriaceae.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6307602     DOI: 10.1159/000238204

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  9 in total

1.  [Rational parameters in the treatment of bacterial meningitis with modern cephalosporins].

Authors:  O Brückner; M Trautmann
Journal:  Infection       Date:  1987       Impact factor: 3.553

2.  A Systematic Review of Studies Reporting Antibiotic Pharmacokinetic Data in the Cerebrospinal Fluid of Critically Ill Patients with Uninflamed Meninges.

Authors:  Nilesh Kumta; Jason A Roberts; Jeffrey Lipman; Wai Tat Wong; Gavin M Joynt; Menino Osbert Cotta
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

Review 3.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

Review 4.  Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.

Authors:  R N Brogden; C M Spencer
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

Review 5.  Pharmacokinetics of anti-infective agents in paediatric patients.

Authors:  D R Butler; R J Kuhn; M H Chandler
Journal:  Clin Pharmacokinet       Date:  1994-05       Impact factor: 6.447

6.  Cefotaxime treatment of gram-negative enteric meningitis in infants and children.

Authors:  R F Jacobs
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 7.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

8.  Cefotaxime pharmacokinetics and treatment of meningitis in neonates.

Authors:  R F Jacobs; G L Kearns
Journal:  Infection       Date:  1989 Sep-Oct       Impact factor: 3.553

9.  Pharmacokinetics of cefotaxime and its desacetyl metabolite in plasma and in cerebrospinal fluid.

Authors:  E Beyssac; J M Cardot; G Colnet; J Sirot; J M Aiache
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Apr-Jun       Impact factor: 2.441

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.